Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Advances in genomics have deepened our understanding of the biology of acute
lymphoblastic leukemia (ALL), defined novel molecular leukemia subtypes, discovered new …

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk B-cell Acute
Lymphoblastic Leukemia (B-ALL) characterized by a gene expression profile similar to Ph …

ABL-class fusions other than BCR-ABL1 characterize around 2–3% of precursor B-cell acute
lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes …

Acute lymphoblastic leukemia (ALL) is a constellation of diseases driven by genetic
alterations commonly derived from structural chromosome rearrangements, aneuploidy and …

High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive disease, often
characterized by resistance to chemotherapy. A frequent feature of high-risk B-ALL is loss of …

The prognosis for children diagnosed with high-risk acute lymphoblastic leukemia (ALL)
remains suboptimal, and more potent and less toxic treatments are urgently needed. We …

Interpreting the function of noncoding mutations in cancer genomes remains a major
challenge. Here, we developed a computational framework to identify putative causal …

Simple Summary B-ALL is the more frequent childhood malignancy. Even though significant
improvements in patients' survival, some pediatric B-ALL have still poor prognosis and novel …